



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## SB-431542 (GMP)

|                    |  |
|--------------------|--|
| Cat. No.:          | HY-10431G  |
| CAS No.:           | 301836-41-9  |
| Molecular Formula: | C <sub>22</sub> H <sub>16</sub> N <sub>4</sub> O <sub>3</sub>  |
| Molecular Weight:  | 384.39   |
| Target:            | TGF-β Receptor   |
| Pathway:           | TGF-beta/Smad  |
| Storage:           | -20°C, sealed storage, away from moisture and light<br>* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |



### BIOLOGICAL ACTIVITY

|                           |   |                                     |                                  |            |                                      |                |       |                  |         |         |  |
|---------------------------|---|-------------------------------------|----------------------------------|------------|--------------------------------------|----------------|-------|------------------|---------|---------|--|
| Description               | SB-431542 (GMP) is <a href="#">SB-431542</a> (HY-10431) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI) in SMAD signaling <sup>[1]</sup> <sup>[2]</sup> <sup>[3]</sup> .  |                                     |                                  |            |                                      |                |       |                  |         |         |  |
| IC <sub>50</sub> & Target | ALK4<br>1 μM (IC <sub>50</sub> )  | ALK5<br>0.75 μM (IC <sub>50</sub> ) | ALK7<br>2 μM (IC <sub>50</sub> ) |            |                                      |                |       |                  |         |         |  |
| In Vitro                  | <p>SB-431542 (GMP) (10 μM; 10 days) induces human pluripotent stem cells (hPSCs) to post-mitotic cortical neurons differentiation<sup>[1]</sup>.</p> <p>SB-431542 (GMP) (10 μM) facilitates directed differentiation into midbrain dopamine neurons (mDA)<sup>[2]</sup>.</p> <p>SB-431542 (GMP) (3.8 μM) promotes differentiation of hPSCs to multipotent hematopoietic progenitors that arise from SOX17<sup>+</sup> hemogenic endothelium in vitro<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>RT-PCR<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human pluripotent stem cells (hPSCs)</td> </tr> <tr> <td>Concentration:</td> <td>10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>10 days</td> </tr> <tr> <td>Result:</td> <td>Showed downregulation of the pluripotency marker OCT4 and induction of neural and neuronal markers PAX6, FOXG1 and DCX, as well as markers of early born cortical neurons, including TBR1 (preplate, subplate and layer VI) and REELIN, in LSB+X/P/S/D conditions.</td> </tr> </table> |                                     |                                  | Cell Line: | Human pluripotent stem cells (hPSCs) | Concentration: | 10 μM | Incubation Time: | 10 days | Result: | Showed downregulation of the pluripotency marker OCT4 and induction of neural and neuronal markers PAX6, FOXG1 and DCX, as well as markers of early born cortical neurons, including TBR1 (preplate, subplate and layer VI) and REELIN, in LSB+X/P/S/D conditions. |
| Cell Line:                | Human pluripotent stem cells (hPSCs)  |                                     |                                  |            |                                      |                |       |                  |         |         |  |
| Concentration:            | 10 μM   |                                     |                                  |            |                                      |                |       |                  |         |         |  |
| Incubation Time:          | 10 days   |                                     |                                  |            |                                      |                |       |                  |         |         |  |
| Result:                   | Showed downregulation of the pluripotency marker OCT4 and induction of neural and neuronal markers PAX6, FOXG1 and DCX, as well as markers of early born cortical neurons, including TBR1 (preplate, subplate and layer VI) and REELIN, in LSB+X/P/S/D conditions.  |                                     |                                  |            |                                      |                |       |                  |         |         |  |

### CUSTOMER VALIDATION

- Immunity. 2022 Mar 15;S1074-7613(22)00124-8.
- Cell Metab. 2022 Aug 15;S1550-4131(22)00313-8.
- Nat Biomed Eng. 2022 Nov 24.

- Gut. 2022 Jan 7;gutjnl-2021-325018.
- Chem Eng J. 1 January 2023, 138737.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Yuchen Qi, et al. Combined small-molecule inhibition accelerates the derivation of functional cortical neurons from human pluripotent stem cells. Nat Biotechnol. 2017 Feb;35(2):154-163.

[2]. Tae Wan Kim, et al. Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use. Cell Stem Cell. 2021 Feb 4;28(2):343-355.e5.

[3]. Monica Nafria, et al. Protocol for the Generation of Definitive Hematopoietic Progenitors from Human Pluripotent Stem Cells. STAR Protoc. 2020 Oct 16;1(3):100130.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA